EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

Efficacy and Safety of Pharmaceutically Manufactured Cannabidiol in Recurrent Pericarditis: A Phase II Clinical Trial

Sushil Allen Luis iD, Allan L Klein iD, Paul C Cremer iD, Antonio Abbate iD, Jonathan R Salik iD, Georgia K Thomas iD, Syed Waqas Haider iD, Tracy E Hagerty, David Lin, Thomas E Waggoner iD, Stephen J Nicholls iD, Bridget-Anne Kirwan und 3 weitere

Journal of the American Heart Association · 21.07.2026 · 15 (14)

DOI: 10.1161/jaha.125.047605 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of the American Heart Association, erschienen am 21.07.2026. Verfasst von Sushil Allen Luis und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine Mayo Clinic Rochester MN USA. Hauptthemen laut MEDLINE: Pericarditis, Cannabidiol. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recurrent pericarditis may be mediated through inappropriate activation of the NACHT, leucine‐rich repeat, and pyrin domain‐containing protein 3 inflammasome. Pharmaceutically manufactured cannabidiol is an oral formulation that inhibits NACHT, leucine‐rich repeat, and pyrin domain‐containing protein 3 inflammasome activation and development of pericarditis in a preclinical model.

Methods

This Phase 2, open‐label, multicenter trial included adult patients with symptomatic recurrent pericarditis: pericarditis chest pain ≥4 on an 11‐point numerical rating scale with an elevated C‐reactive protein (≥1 mg/dL) or at least mild pericardial inflammation on cardiac magnetic resonance imaging. At enrollment, patients were on stable doses of non‐steroidal anti‐inflammatory drugs, colchicine, and/or corticosteroids. Cannabidiol was administered during an 8‐week treatment period and an optional 18‐week extension period when background therapy was tapered and discontinued. The primary efficacy end point was change in patient‐reported pericarditis pain. Secondary end points included normalization of C‐reactive protein and percentage of patients with recurrences.

Results

Among 27 patients (18 women, mean age 53 years), baseline maximal numerical rating scale pain score was 5.8±1.7, and 10 patients had elevated C‐reactive protein. At Week 8, maximal numerical rating scale pain score was 2.1±1.8, and median time to numerical rating scale score ≤2 was 5 days. Among the 10 patients with baseline C‐reactive protein elevation, C‐reactive protein was normal at Week 8 in 8 patients (80%). During the extension period, 17 (71%) of 24 patients remained free of pericarditis recurrence. A serious adverse event leading to cannabidiol discontinuation occurred in 1 patient.

Conclusions

In symptomatic patients with recurrent pericarditis, pharmaceutically manufactured cannabidiol appears safe and associated with reductions in pericarditis pain and systemic inflammation. Registration URL: clinicaltrials.gov ; Unique Identifier: NCT05494788.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PericarditisCannabidiolHumansFemaleMiddle AgedMaleRecurrenceTreatment OutcomeAdultC-Reactive ProteinAnti-Inflammatory Agents, Non-SteroidalColchicineAged

Stichwörter der Autor:innen

cannabidiolclinical trialinflammationpericarditis

Substanzen

CannabidiolC-Reactive ProteinAnti-Inflammatory Agents, Non-SteroidalColchicine

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine Mayo Clinic Rochester MN USA.
  • Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine Heart, Vascular and Thoracic Institute, Cleveland Clinic Cleveland OH USA.
  • Departments of Medicine and Radiology, and Multimodality Cardiac Imaging and Clinical Trials Unit Bluhm Cardiovascular Institute, Northwestern University Chicago IL USA.
  • Berne Cardiovascular Research Center University of Virginia Charlottesville VA USA.
  • Cardiology Division Massachusetts General Hospital, Harvard Medical School Boston MA USA.
  • Virginia Commonwealth University Health System Richmond VA USA.

ORCID-Profile: Sushil Allen Luis, Allan L Klein, Paul C Cremer, Antonio Abbate, Jonathan R Salik, Georgia K Thomas, Syed Waqas Haider, Thomas E Waggoner, Stephen J Nicholls, Kelly A D Narine

Zitieren

APA

Luis, S. A., Klein, A. L., Cremer, P. C., Abbate, A., Salik, J. R., Thomas, G. K., Haider, S. W., Hagerty, T. E., Lin, D., Waggoner, T. E., Nicholls, S. J., Kirwan, B. A., Narine, K. A. D., Parker, A. B., & Hamer, A. (2026). Efficacy and Safety of Pharmaceutically Manufactured Cannabidiol in Recurrent Pericarditis: A Phase II Clinical Trial. Journal of the American Heart Association, 15(14). https://doi.org/10.1161/jaha.125.047605

Vancouver

Luis SA, Klein AL, Cremer PC, Abbate A, Salik JR, Thomas GK, et al. Efficacy and Safety of Pharmaceutically Manufactured Cannabidiol in Recurrent Pericarditis: A Phase II Clinical Trial. Journal of the American Heart Association. 2026;15(14). doi:10.1161/jaha.125.047605

BibTeX
@article{Luis2026,
  author = {Luis, Sushil Allen and Klein, Allan L and Cremer, Paul C and Abbate, Antonio and Salik, Jonathan R and Thomas, Georgia K and Haider, Syed Waqas and Hagerty, Tracy E and Lin, David and Waggoner, Thomas E and Nicholls, Stephen J and Kirwan, Bridget-Anne and Narine, Kelly A D and Parker, Andrea B and Hamer, Andrew},
  title = {Efficacy and Safety of Pharmaceutically Manufactured Cannabidiol in Recurrent Pericarditis: A Phase II Clinical Trial},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {14},
  doi = {10.1161/jaha.125.047605}
}
Kostenlos starten →